%0 Journal Article %T Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension %A Charles Burger %A Cher Y. Enderby %J Archive of "Therapeutic Advances in Chronic Disease". %D 2018 %R 10.1177/2040622318779749 %X Treprostinil is a prostacyclin analogue that directly vasodilates pulmonary and systemic arterial vascular beds. The United States Food and Drug Administration approved inhaled treprostinil in July 2009 for the treatment of group 1 pulmonary arterial hypertension. Inhaled treprostinil avoids issues with continuous infusion prostanoids. This study describes a single institutional experience with inhaled treprostinil %K treprostinil %K pulmonary arterial hypertension %U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116084/